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ABSTRACT
Objective: Published evidence indicates that surgical
drainage of the pancreatic duct was more effective than
endoscopic drainage for patients with chronic
pancreatitis. This analysis assessed the cost-
effectiveness of surgical versus endoscopic drainage in
obstructive chronic pancreatitis.
Design: This trial-based cost-utility analysis
(ISRCTN04572410) was conducted from a UK National
Health Service (NHS) perspective and during a
79-month time horizon. During the trial the details of
the diagnostic and therapeutic procedures, and
pancreatic insufficiency were collected. The resource
use was varied in the sensitivity analysis based on a
review of the literature. The health outcome was the
Quality-Adjusted Life Year (QALY), generated using
EQ-5D data collected during the trial. There were no
pancreas-related deaths in the trial. All-cause mortality
from the trial was incorporated into the QALY estimates
in the sensitivity analysis.
Setting: Hospital.
Participants: Patients with obstructive chronic
pancreatitis.
Primary and secondary outcome measures:
Costs, QALYs and cost-effectiveness.
Results: The result of the base-case analysis was that
surgical drainage dominated endoscopic drainage,
being both more effective and less costly. The
sensitivity analysis varied mortality and resource use
and showed that the surgical option remained
dominant in all scenarios. The probability of cost-
effectiveness for surgical drainage was 100% for the
base case and 82% in the assessed most conservative
case scenario.
Conclusions: In obstructive chronic pancreatitis,
surgical drainage is highly cost-effective compared
with endoscopic drainage from a UK NHS perspective.
Chronic pancreatitis is a progressive inﬂam-
matory disorder, which can cause abdominal
pain, various local complications and endo-
crine–exocrine pancreatic insufﬁciency.
When chronic pancreatitis is associated with
an obstructed pancreatic duct, a suitable
therapy is ductal decompression, using an
endoscopic or a surgical approach.
Published evidence having compared
endoscopic and surgical procedures in
patients with chronic pancreatitis and an
obstructed pancreatic duct showed that surgi-
cal drainage of the pancreatic duct was more
effective than endoscopic drainage in terms
of pain relief and number of follow-up proce-
dures.1–3 However, surgery is a more costly
procedure than endoscopy and is believed to
be associated with a higher risk of mortality.
This trial-based economic analysis aimed to
assess the cost-effectiveness of surgical drain-
age of the pancreatic duct compared with
endoscopic drainage, for patients with
chronic pancreatitis and an obstructed
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The robustness of the results was assessed in
the sensitivity analysis by varying relevant esti-
mates using outcomes from reviews of the
literature.
▪ All analyses were probabilistic; applying probabil-
ity distributions to each model parameter and
allowing estimation of the empirical distribution
of the cost-effectiveness results.
▪ The limited randomised evidence on the topic
led to develop this analysis based on a single
trial with a relatively small sample size.
▪ The analysis did not include primary care costs
associated with the follow-up of patients in the
community. However, such costs are likely to be
small compared with the cost of procedures and
hospitalisation. This analysis was developed
from a UK perspective and using collected data
in the Netherlands. Caution is recommended
before the results are extrapolated to other
settings.
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pancreatic duct, and combined resource use, cost, mor-
tality and patient’s quality-of-life data.
A cost-utility model was originally developed by the
National Clinical Guideline Centre, Royal College of
Physicians of London based on the 24-month aggregated
resource use data from the Cahen trial1 This was con-
ducted as part of the development process of the
Clinical Guideline on Alcohol Use Disorders, which was
commissioned and funded by the National Institute for
Health and Care Excellence (NICE).4 This original ana-
lysis concluded that surgery was highly cost-effective
compared with endoscopy and led to the recommenda-
tion by NICE that National Health Service (NHS)
healthcare providers should ‘Offer surgery, in prefer-
ence to endoscopic therapy, to people with pain from
large-duct (obstructive) chronic alcohol-related pancrea-
titis’.4 Second, when the long-term follow-up data from
the Cahen trial (mean 79 months) became available, it
was found that the cost per patient was $6006 higher in
the endoscopy group, but this difference was not statis-
tically signiﬁcant (95% CI, $16 188 to $27 786; p=0.29).3
At this time point, there were no longer differences in
quality-of-life (SF-36) and health utility (EQ-5D based)
scores. We present a trial-based cost-utility analysis, based
on this long-term follow-up data.
The Cahen trial1 3 (the trial) included symptomatic
patients with chronic pancreatitis and a distal obstruc-
tion of the pancreatic duct (without an inﬂammatory
mass). Thirty-nine patients underwent randomisation: 19
to endoscopic transampullary drainage of the pancreatic
duct and 20 to operative pancreaticojejunostomy. In the
endoscopy group, following a sphincterotomy and dila-
tion of the pancreatic duct stricture, a 10-French
Amsterdam biliary stent was inserted and the stricture
reassessed at 3 months. Persistent strictures were treated
by repeated dilation and sequential insertion of multiple
stents. Extracorporeal shock-wave lithotripsy was used if
there were one or more intraductal stones more than
7 mm in diameter. In the surgical group, a pancreatico-
jejunostomy was performed in 18 patients by the
method of Partington and Rochelle. The pancreatic
duct was incised over the full length up to 2 cm from
the ampulla. When retrieval of concretions from the
head area required further opening of the duct towards
the ampulla, a limited wedge resection of pancreatic
tissue was performed. In one patient, a Whipple proced-
ure was performed because of peripancreatic inﬂamma-
tion. In another patient, stone extraction required a Frey
procedure. The baseline demographic and clinical char-
acteristics of patients in the two treatment groups were
similar, with the exception of ongoing alcohol abuse
(n=5 in the surgery group; n=0 in the endoscopy group;
p=0.05).1 One patient was lost to follow-up at 6 months
after undergoing surgery and was excluded from the
analysis.3 The results of the trial1 3 concluded that initial
surgical drainage of the pancreatic duct is superior to
endoscopic treatment in symptomatic patients with
advanced chronic pancreatitis, not only based on short-
term outcomes but also in the long term. These beneﬁts
apply for pain relief and the need for reintervention.
METHOD
Overview
This cost-effectiveness analysis was built from the trial
data from randomisation to end of the long-term patient
follow-up (mean of 79 months).1 3 The trial was
approved by the medical ethics committee of the
Academic Medical Center, Amsterdam, controlled Trials
number ISRCTN04572410.
The analysis was developed from an England and Wales
NHS perspective using the NICE reference case.5 The
measure of health outcome was the Quality-Adjusted Life
Year (QALY). The time horizon used was the mean
follow-up of 79 months of the trial.3 An annual discount
rate of 3.5% was applied to both costs and health out-
comes incurred after 1 year, as is standard practice for
health economic evaluations conducted for the NHS.5
Utility scores
In the trial,1 3 the EuroQol 5 dimensions questionnaire
(EQ-5D)6 was completed by patients (3-level EQ-5D).
The EQ-5D is a generic health state preference
measure.7 Data were collected for each arm at baseline,
6 weeks, 3, 6, 12, 18, 24 and 79 months. We used patient-
level EQ-5D data from the trial and generated utility
scores for both arms at every follow-up point. The
health state preference values (utilities) for EQ-5D pro-
ﬁles were based on time-trade-off valuations by members
of the UK general public.7 Mean imputation was used to
manage missing data. Because the baseline utility scores
differed slightly between arms (0.335 vs 0.275; table 1),
the between-arm difference in utility score at each time
point was adjusted for differences in baseline utility as
proposed by Manca et al (2005),8 by applying ordinary
least squares linear regression in SPSS 15.0 with baseline
utility and trial arm as the only covariates. Because long-
term EQ-5D data (post 24 months) were collected only
at 79 months, and no difference between groups was
demonstrated at 79 months (endoscopy 0.79±0.21;
surgery 0.82±0.26; difference −0.03, 95% CI (−0.20 to
0.14), p=0.75)3, after 24 months we assumed no differ-
ence in utility score between the cohorts and applied a
constant utility score of 0.79 (from the endoscopy
group) to both groups. The QALYs in the endoscopy
group were estimated by assuming a linear transition
between the mean utilities at each time point (using the
data from the endoscopy column of table 1). For the
surgery group, the QALYs were also calculated assuming
a linear transition (but at each time point the utility for
surgery was the sum of the endoscopy utility and the
increment of that time point from table 1).
Mortality
During the mean follow-up time of 79 months (SD, 24)
of the study,3 three patients died in the endoscopy
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group and four in the surgery group. One early death
was reported within 24 months: this endoscopically
treated patient died of a perforated duodenal ulcer.
After 24 months, another six patients died at a median
time of 45 months (range, 27–59 months): two in the
endoscopy group (pulmonary carcinoma; cardiovascular
disease) and four in the surgery group (myocardial
infarction; sepsis; neuroendocrine tumour; oropharyn-
geal carcinoma). As these deaths were unrelated to pan-
creatitis, these were not considered in the base case of
this cost-effectiveness analysis but were included in the
sensitivity analysis. In the sensitivity analysis, a utility of
zero was applied from the death for each death in the
trial.
Resource use and costs
The details of the use of diagnostic and therapeutic pro-
cedures, the treatment of pancreatic exocrine and endo-
crine insufﬁciency, and the time in hospital were
collected during the trial. We combined this
resource-use data with the most recent UK unit costs.9–11
Diagnostic procedures and therapeutic procedures
(including the hospital stay) were costed using the
2010–2011 National Schedule of Reference Costs.9
Tables 2 and 3 present the diagnostic and the thera-
peutic procedures performed during the trial and their
UK unit cost.1 3
Changes in pancreatic function (endocrine and exo-
crine) were assessed during the trial. Based on the
79-month results,3 and adjusting for baseline function,
the proportion of patients for whom insufﬁciency per-
sisted, resolved, developed and for whom sufﬁciency per-
sisted were estimated for each trial arm. For exocrine
insufﬁciency, treatment with pancreatic enzyme supple-
mentations was costed for 79 months in patients whose
insufﬁciency persisted (endoscopy 74%; surgery 63%),
and for 39.5 months in patients whose insufﬁciency
developed (endoscopy 26%; surgery 26%) or resolved
(endoscopy 0%; surgery 11%). All patients were
recorded as having exocrine insufﬁciency at some point.
The treatment for exocrine insufﬁciency was assumed to
be eight capsules a day of Creon 25 000 current practice
in England (daily cost of £2.26).10
For costing endocrine function, we used a yearly cost
of £939 for a regimen of two injections per day of a
biphasic insulin preparation. This is the lower yearly cost
reported by the GINGER study economic evaluation
assessing treatments for type 2 diabetes.12 This cost is
still current according to the most recent MIMS, April
2013.11 The treatment cost for endocrine function was
calculated for 79 months in patients whose endocrine
insufﬁciency persisted (endoscopy 26%; surgery 26%),
and for 39.5 months in patients whose insufﬁciency
developed (endoscopy 43%; surgery 20%). The remain-
ing patients did not experience any endocrine insufﬁ-
ciency (endoscopy 31%; surgery 54%).
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Sensitivity analysis
Sensitivity analyses were performed to assess the robust-
ness of the results. Two scenarios were tested. The ﬁrst
incorporated all-cause mortality from the long-term
follow-up of the trial.3 The second was a more conserva-
tive case scenario, in which estimates for key parameters
were used that were less favourable to surgical drainage.
In this scenario, parameters associated with the number
of therapeutic procedures (the highest cost component)
were altered from the base case: (1) conversion to
surgery in the endoscopy group; (2) additional endo-
scopic drainage required in the endoscopy group and
(3) additional surgical drainage required in the surgery
group. In addition, the all-cause mortality from the trial
Table 2 Diagnostic procedures
Procedure
(cost per procedure9)
Endoscopy group (n=19) Surgery group (n=19)
Number of
procedures
Mean number
per patient SD
Number of
procedures
Mean number
per patient SD
Abdominal CT scan (£168) 13 0.68 0.95 26 1.37 1.46
MR cholangiopancreatography
(£190)
17 0.89 1.20 18 0.95 1.78
Abdominal ultrasound (£50) 17 0.89 1.15 28 1.47 1.87
Endoscopic ultrasound (£591) 5 0.26 0.45 1 0.05 0.23
Gastroscopy (£337) 6 0.32 0.58 7 0.37 0.76
Colonoscopy (£638) 3 0.16 0.50 – – –
Flexible sigmoidoscopy (£638) 1 0.05 0.23 – – –
Radiography (£29) 32 1.68 7.10 3 0.16 0.50
Missing data* (£157) 2 0.11 0.32 – – –
All 96 5.05 8.15 83 4.37 5.10
*To cost the missing data, we used the weighted average cost of the diagnostic procedures undergone in the endoscopy group.
Table 3 Therapeutic procedures*
Procedure (cost per procedure; mean hospital stay9)
Number of
procedures
Mean number
per patient SD
Endoscopy group (n=19)
Extracorporeal shock-wave lithotripsy session (followed by an endoscopy
procedure) (£591; day case)
27 1.42 1.22
Extracorporeal shock-wave lithotripsy session (for stones, without subsequent
stenting) (£591; day case)
6 0.32 0.67
Pancreaticojejunostomy (£6921; 6.6 days) 9 0.47 0.61
Endoscopic retrograde cholangiopancreatography (£1488; 2.2 days) 120 6.32 3.32
Endoscopic ultrasound-guided coeliac blockage (£902; day case) 3 0.16 0.37
Cholecystectomy (£2844; 2.5 days) 1 0.05 0.23
Hepaticojejunostomy and Frey procedure (£6921; 6.6 days) 1 0.05 0.23
Frey procedure (£6921; 6.6 days) 1 0.05 0.23
Abscess drainage (£1488; 2.2 days) 1 0.05 0.23
Feeding tube insertion (nasojejunal tube) (£337; N/A) 21 1.11 2.54
Transcutaneous electrical nerve stimulation (TENS) (£575; day case) 1 0.05 0.23
Surgical block of splanchnic sympathetic nerve (£1701; 1.8 days) 1 0.05 0.23
Percutaneous gastrostomy (£919; 1.1 days) 1 0.05 0.23
Umbilical hernia procedure (£2004; 1.5 days) 1 0.05 0.23
Procedure for repair leakage (£6921; 6.6 days) 1 0.05 0.23
All 195 10.26 5.67
Surgery group (n=19)
Frey procedure (£6921; 6.6 days) 1 0.05 0.23
Whipple procedure (£8469; 7.3 days) 1 0.05 0.23
Pancreaticojejunostomy (£6921; 6.6 days) 17 0.89 0.32
Endoscopic retrograde cholangiopancreatography (£1488; 2.2 days) 8 0.42 1.61
Procedure for repair leakage (£6921; 6.6 days) 1 0.05 0.23
Feeting tube insertion (nasojejunal tube) (£337; N/A) 14 0.74 2.58
Distal pancreatic resection procedure (£6921; 6.6 days) 1 0.05 0.23
Pain block procedure (£902; day case) 4 0.21 0.63
All 47 2.47 3.32
*The cost of therapeutic procedures is including the cost for hospital stay.
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was also incorporated into this more conservative case
scenario.3
Conversion to surgery in the endoscopy group
During the 79-month follow-up period of the trial,3 47%
(9/19) of the patients in the endoscopy group con-
verted to surgery as the endoscopic treatment was con-
sidered to have failed. Clinical studies assessing
endoscopic drainage for treating patients with chronic
pancreatitis were reviewed for the NICE Clinical
Guideline on Alcohol Use Disorders4 for rates of conver-
sion to surgery (databases were searched for the guide-
line up to 22 June 2009). It showed probabilities varying
between 0% and 26% (overall 19%).1 2 13–20 This overall
value of 19% was used in the sensitivity analysis.
Additional endoscopic drainage required in the endoscopy
group
During the 79-month follow-up period of the trial,3 68%
(13/19) of the patients in the endoscopy group required
additional endoscopic drainage. Clinical studies assessing
endoscopic drainage for treating patients with chronic
pancreatitis were reviewed by the NICE Clinical Guideline
on Alcohol Use Disorders4 for stent-related dysfunction/
complication rates (databases were searched for the guide-
line up to 22 June 2009). It showed probabilities varying
between 3% and 55% (overall 15%).1 15–19 21 This overall
value of 15% was used in the sensitivity analysis.
Additional surgical drainage required in the surgery group
During the 79-month follow-up period of the trial,3 5%
(1/19) of the patients in the surgery group required add-
itional surgical drainage. Clinical studies assessing surgery
for treating patients with chronic pancreatitis were
reviewed by the NICE Clinical Guideline on Alcohol Use
Disorders4 for rates of reoperation (databases were
searched for the guideline up to 22 June 2009). After val-
idation of this review, it showed reoperation rates varying
between 2.6% and 17.5% (overall 8.8%).1 2 22–25 The
higher value of 17.5% was used in the sensitivity analysis.
Mortality
From a review of clinical studies for the NICE Clinical
Guideline on Alcohol Use Disorders4 (databases were
searched for the guideline up to 22 June 2009), the mortal-
ity related to surgical drainage was estimated to be
0.9%.1 2 22–29 During the mean follow-up time of 79 months
of the trial,3 three patients died in the endoscopy group
and four in the surgery group. These deaths were unrelated
to pancreatitis, and thus not considered in the base case.
All-cause mortality was, however, considered in the sensitivity
analyses in which mortality risks of 15.8% (3/19) to the
endoscopy group and 21.1% (4/19) to the surgical group
were applied. This accounts for a difference of 5.3%, a
much higher estimate than those observed in the literature
for mortality related to surgical drainage, allowing assessing
a conservative case scenario against surgery.
Statistical analysis
This economic analysis, conducted in MS Excel 2010,
presents all results probabilistically including sensitivity
analyses. A probabilistic analysis, using Monte Carlo
simulation, applies probability distributions to each
model parameter, allowing estimation of the empirical
distribution of the cost-effectiveness results.30 A γ distri-
bution was applied to cost estimates (bounded at 0).
The cost of therapeutic and diagnosis procedures, taken
from the 2010 to 2011 National Schedule of Reference
Costs,9 were varied using their IQR: the SE of each
mean unit cost was estimated manually so that the 25th
and 75th centiles of the γ distribution to most closely
ﬁtted the published IQR of the unit cost. The costs for
pancreatic insufﬁciency treatments were varied in a
range of ±20% using a uniform distribution. The distri-
butions were applied to each unit cost before the unit
costs were combined with the resource use frequency
taken from the trial, and before discounting. For each
item of resource use the frequency was given a β distri-
bution (bounded between 0 and 1). A β distribution was
also applied in the same context to the probability esti-
mates for pancreatic function from the trial. A β distri-
bution was also applied to the mortality risks from the
trial considered in the sensitivity analysis.
In addition to the adjustment for baseline imbalance
from the trial applied to pancreatic function (endocrine
and exocrine), baseline adjustment was applied to one
other trial estimate as appropriate: the utility scores. As
mentioned earlier, the between-arm difference in utility
score at each time point was adjusted for differences in
baseline utility by applying ordinary least squares linear
regression. The resulting coefﬁcient (increment for
surgery) and its SE were then used as inputs in the prob-
abilistic cost-effectiveness. More speciﬁcally, at each time
point up to 24 months, a β distribution was applied to
the utilities of the endoscopy arm and a normal distribu-
tion to the increment for surgery estimated when adjust-
ing for baseline differences (table 1; the distribution for
each utility in the surgery arm was the sum of the utility
in the endoscopy arm and the increment but was trun-
cated at 1). Then, from 24 to 79 months, a β distribution
was applied to the constant same utility score considered
for compared arms as explained earlier.
Results of the base-case and sensitivity analyses were
recalculated 5000 times, with all model parameters set
simultaneously, each selected at random from the
respective parameter distribution. Results presented are
the mean of the 5000 computed simulations. This
approach was chosen to account for the uncertainty
around the unit cost parameters as well as trial outcomes.
To estimate a two-sided p value for the incremental
cost we took the proportion of the 5000 simulations
where costs were lower for endoscopy than for surgery
and then multiplied by two. We applied the same
approach to the QALYs gained. To estimate CIs, we took
the 2.5th and 97.5th centiles from the 5000 simulations.
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A limitation of our approach is that it does not
capture the covariance between the utility at different
time points or between resource use and utility, as each
is considered independent. This is a limitation with
regard to estimating the level of statistical signiﬁcance
but not with regard to our point estimates.
RESULTS
Quality-adjusted life years
We used the utility scores (endoscopy and increment)
presented in table 1 to calculate QALYs for the
24-month trial duration, and applied, from 24 to
79 months to both groups the constant utility score of the
endoscopy group at 79 months (0.79±0.21).3 Considering
the higher score at 24 months for the surgery group, this
assumption after 24 months was conservative, that is to say
biasing against surgery. When no difference in mortality
was assumed, the QALY difference at 79 months was 0.44
in favour of surgery (p<0.001; table 4). When all-cause
mortality from the trial was captured, the QALY difference
still favoured surgery (difference of 0.22, CI: −0.77 to
0.36), but the difference was no longer statistically signiﬁ-
cant (table 5).
Resource use and cost
Cost results are reported in 2011 pound sterling.
Combining the frequency of each diagnostic and thera-
peutic procedure performed during the trial1 3 with UK
unit costs from the 2010 to 2011 National Schedule of
Reference Costs9 (tables 2 and 3), we found a higher cost
for endoscopy for both diagnostic and therapeutic
procedures. However, the difference only reached statis-
tical signiﬁcance for the therapeutic procedures (£5943/
patient, 95% CI: £86 to 13 290; table 4). The costs of
treating exocrine and endocrine insufﬁciency were
higher for the endoscopy group but these differences did
not reach statistical signiﬁcance (table 4). The total cost
for the base-case favoured surgery with a statistically sig-
niﬁcant difference of £7033/patient (95% CI 869 to
14 638).
In the sensitivity analysis, data from reviews of the lit-
erature were used to vary the cost of therapeutic proce-
dures, so as to test a more conservative case scenario for
surgical drainage. The surgery group showed a slightly
lower cost for therapeutic procedures (£81, 95% CI: −
£5574 to £5780). However, this difference was no longer
statistically signiﬁcant (table 5). The total cost for the
sensitivity analysis favoured surgery, but this difference of
£1170 did not reach statistical signiﬁcance (95% CI
−4671 to 7066).
Cost-effectiveness
The result of the base-case analysis was that surgical
drainage of the pancreatic duct dominates endoscopic
drainage (it was more effective and less costly—tables 4
and 6). The sensitivity analysis showed that the surgical
option remains dominant (cost-saving and QALY
increasing) in all scenarios, even under the assessed
most conservative case scenario (table 6). In the sensitiv-
ity analysis, the total cost and QALY differences between
surgery and endoscopy were not statistically signiﬁcant
(table 5). However, the probability that surgery is cost-
Table 4 Base-case analysis results: mean costs and QALYs/patient*
Endoscopy mean
(SD)
Surgery mean
(SD) Difference (endoscopy-surgery)
Diagnostic procedures cost £831 (208) £622 (154) £210 (221) (95% CI −186 to 704) (p=0.301)
Therapeutic procedures cost £14797 (3,393) £8853 (2580) £5943 (3334) (95% CI 86 to 13290) (p=0.047)
Pancreatic exocrine function
cost
£4219 (1936) £3956 (1885) £264 (779) (95% CI −1185 to 1912) (p=0.701)
Pancreatic endocrine
function cost
£2596 (222) £1980 (530) £616 (503) (95% CI −420 to 1546) (p=0.225)
Total cost £22443 (3936) £15410 (3262) £7033 (3457) (95% CI 869 to 14638) (p=0.030)
QALYs 3.90 (0.18) 4.34 (0.19) −0.44 (0.09) (95% CI −0.61 to −0.27) (p<0.001)
*Discounted at 3.5%.
QALY, Quality-Adjusted Life Year.
Table 5 Sensitivity analysis results: mean costs and QALYs/patient*
Endoscopy mean
(SD)
Surgery mean
(SD) Difference (endoscopy-surgery)
Therapeutic procedures cost £9805 (2328) £9725 (2828) £81 (2804) (95% CI −5574 to 5780) (p=0.973)
Total cost £17451 (3060) £16281 (3462) £1170 (2949) (95% CI −4671 to 7066) (p=0.684)
QALYs (all-cause mortality) 3.58 (0.23) 3.80 (0.28) −0.22 (0.28) (95% CI −0.77 to 0.36) (p=0.415)
*Discounted at 3.5%.
QALY, Quality-Adjusted Life Year.
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effective compared with endoscopy, assuming a threshold
of £20 000/QALY gained was 82% (100% in the base
case; table 6 and ﬁgure 1). The probability that surgery
is cost-saving compared with endoscopy was 65.8% in the
sensitivity analysis (98.8% in the base case).
DISCUSSION
On the basis of the 24-month aggregated results from
the trial,1 an original cost-effectiveness model was devel-
oped to inform recommendations for the NICE Clinical
Guideline on Alcohol Use Disorders.4 Based on the
results from the model showing that surgery is cost-
effective compared with endoscopy, NICE recom-
mended to ‘Offer surgery, in preference to endoscopic
therapy, to people with pain from large-duct (obstruct-
ive) chronic alcohol-related pancreatitis’.4
The trial was extended to a long-term patient
follow-up of a mean of 79 months,3 and the results led
to conclude that, in patients with chronic pancreatitis
and an obstructed pancreatic duct, initial surgical drain-
age of the pancreatic duct is superior to endoscopic
treatment in symptomatic patients with advanced
chronic pancreatitis, not only based on short-term out-
comes but also in the long term. These beneﬁts include
greater pain relief and reduced need for reinterven-
tion.3 However, surgery is a more costly procedure than
endoscopy, and therefore it has been unclear whether
these beneﬁts are greater enough to justify both the
initial investment and the risks associated with surgery.
We thus aimed to combine resource use, quality of life
and mortality data from the trial, along with UK unit
costs, to assess the cost-effectiveness of surgical drainage
compared with endoscopic drainage.
This trial-based cost-effectiveness analysis was devel-
oped from a UK perspective and using data collected in
the Netherlands. The trial results are transferable to the
UK because of the reasonable similarity in terms of
patient population, clinical practices and healthcare
organisation. It is common practice in health economics
to estimate the cost-effectiveness of an intervention from
the perspective of one health system using the best avail-
able trial evidence conducted in a different country.
However, even if it is accepted that the results of this
cost-effectiveness analysis are sound from a UK perspec-
tive, a comparison of care pathways and unit costs
should be made before the results of this study are extra-
polated to other settings.
The current economic analysis considered the cost of
diagnosis procedures, treatment of pancreatic function
and therapeutic procedures with the associated hospital
stay. The cost of the therapeutic procedures included the
original treatment for pancreatitis, retreatment(s) and the
treatment of complications. The analysis did not include
primary care costs associated with the follow-up of patients
in the community. However, such costs are likely to be
small compared with the cost of procedures and hospital-
isation, and therefore would not affect the conclusions.Ta
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The limited randomised evidence on the topic led to
this analysis being based on a single trial with a relatively
small sample size. Nevertheless, the uncertainty around
all estimates was accounted for by the probabilistic ana-
lysis, which allowed estimation of the empirical distribu-
tion of results and the statistical signiﬁcance of the
differences. Additionally, we conducted sensitivity analyses
which conﬁrmed the robustness of the conclusions that
surgery is cost-saving and highly cost-effective compared
with endoscopy, even under conservative assumptions.
Although the study size was relatively small, the prob-
ability that surgery is cost-effective was very high across
the analyses. This was mainly due to the large improve-
ments in quality of life at each follow-up point for the
ﬁrst 24-month period, as measured by the EQ-5D. The
model showed that, in terms of QALYs, the large bene-
ﬁts from improved quality of life outweigh the QALYs
lost due to increased risk of mortality, even under a con-
servative assumption: the difference in all-cause mortal-
ity of 5.3% applied in the sensitivity analysis is much
Figure 1 Cost-effectiveness scatter plots.
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higher than the reported mortality associated with surgi-
cal drainage (0.9%).4
The baseline demographic and clinical characteristics
of patients in the two treatment groups were similar,
with the exception of ongoing alcohol abuse (n=5 in the
surgery group; n=0 in the endoscopy group; p=0.05). We
did not adjust for this when analysing the EQ-5D data
nor did we estimate productivity losses, but if we had
these are both likely to favour surgery.
Another trial (Dite 20032) comparing endoscopic and
surgical procedures in patients with chronic pancreatitis
and an obstructed pancreatic duct showed that, in terms
of pain relief, surgical drainage of the pancreatic duct
was more effective than endoscopic drainage. No
quality-of-life assessment was undertaken in this trial2
and limited resource-use evidence was reported.
Furthermore, extracorporeal shock-wave lithotripsy was
not used in the Dite 2003 trial,2 making it less relevant
to current practice than the trial we used in our ana-
lysis.3 Nevertheless, outcomes from Dite 20032 were con-
sidered in the sensitivity analysis by varying the rate of
conversion to surgery and the reoperation rate, which
did not change the conclusion of the base-case cost-
effectiveness assessment.
A retrospective study31 from Japan based on medical
records compared the resource use and medical cost
associated with endoscopic drainage versus surgical
drainage in patients with painful chronic calciﬁed pan-
creatitis. A total of 68 patients were classiﬁed into endos-
copy group (n=34) or surgery group (n=34). Patients
receiving endoscopy were further divided into two sub-
groups: a short-period group—patients who could dis-
continue serial pancreatic stenting within 1 year (n=19);
and a long-period group—patients who needed pancre-
atic drainage by serial endoscopic stenting for more
than 1 year (n=15). This study concluded that patients
in the long-period endoscopy group required signiﬁ-
cantly longer hospital stays, more frequent hospitalisa-
tions and had higher medical expenses than both
the short-period endoscopic treatment group and the
surgery group. No difference was found between the
short-period endoscopy group and the surgery group.
This study is more open to bias being a retrospective
observational study, and the results from the analysis
have been inﬂuenced by the choice of subgroups com-
pared. The results, however, do suggest that it may be
less costly to initiate treatment with surgery or to change
approach before 1 year in the case of serial endoscopic
stenting.
The total cost results in the current trial-based eco-
nomic analysis showed for the base case that surgical
drainage is less costly than endoscopy and this differ-
ence is statistically signiﬁcant. These results were driven
by a difference in the incidence of subsequent thera-
peutic procedures. In a previous comparative cost ana-
lysis of the long-term (79-month) results from the trial,3
it was shown that surgery was less costly but this differ-
ence did not reach statistical signiﬁcance. The main
reason that this study did not show statistical signiﬁcance
when the current study does is due to the inclusion of
the cost of treating endocrine insufﬁciency in the
current study.
In conclusion, surgical drainage of the pancreatic duct
is highly cost-effective compared with endoscopic drain-
age for treating patients with chronic pancreatitis and
an obstructed pancreatic duct in England and Wales.
This conclusion was robust to sensitivity analysis. Also
this analysis demonstrates that surgery is cost saving com-
pared with endoscopy when considering all cost compo-
nents related to patient care in chronic pancreatitis.
This trial-based cost-effectiveness analysis lends further
support to the NICE recommendation to ‘Offer surgery,
in preference to endoscopic therapy, to people with
pain from large-duct (obstructive) chronic alcohol-
related pancreatitis’. However, the results should only be
generalised to other healthcare systems with caution.
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